{"id":5784,"date":"2021-03-03T09:46:07","date_gmt":"2021-03-03T17:46:07","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=5784"},"modified":"2021-03-04T09:48:33","modified_gmt":"2021-03-04T17:48:33","slug":"preliminary-efficacy-of-the-nvx-cov2373-covid-19-vaccine-against-the-b-1-351-variant","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/03\/preliminary-efficacy-of-the-nvx-cov2373-covid-19-vaccine-against-the-b-1-351-variant\/","title":{"rendered":"Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant"},"content":{"rendered":"<ul>\n<li><i>[Pre-print, not peer-reviewed]<\/i> Results from a multicenter, randomized, observer-blinded, placebo-controlled trial in South Africa of the NVX-CoV2373 (Novavax) nanoparticle vaccine indicated that among 2,684 participants who were SARS-CoV-2 seronegative at baseline (94% HIV-negative; 6% people living with HIV), vaccine efficacy was 49.4%, with 15 and 29 predominantly mild to moderate COVID-19 cases in vaccine and placebo recipients, respectively. Efficacy in HIV-negative participants was 60.1% and did not differ by baseline SARS-COV-2 serostatus.\u00a0Of the primary endpoint COVID-19 cases with available whole genome sequencing, 38 (92.7%) of 41 were the B.1.351 variant.<\/li>\n<li>One notable finding from the study was that among placebo recipients, the incidence of symptomatic COVID-19 was similar in those with and without evidence of antibodies against SARS-CoV-2 at baseline during the first 2 months of follow-up (5.3% vs 5.2%).\u00a0\u00a0The authors conclude that this suggests prior infection provided no protection against developing clinical disease when infected with the B.1.351 variant.<\/li>\n<\/ul>\n<p><i>Shinde et al. (Mar 3, 2021). Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant. Pre-print downloaded Mar 3 from <\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.02.25.21252477\">https:\/\/doi.org\/10.1101\/2021.02.25.21252477<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Results from a multicenter, randomized, observer-blinded, placebo-controlled trial in South Africa of the NVX-CoV2373 (Novavax) nanoparticle vaccine indicated that among 2,684 participants who were SARS-CoV-2 seronegative at baseline (94% HIV-negative; 6% people living with HIV), vaccine efficacy was 49.4%, with 15 and 29 predominantly mild to moderate COVID-19 cases in vaccine and&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/03\/preliminary-efficacy-of-the-nvx-cov2373-covid-19-vaccine-against-the-b-1-351-variant\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33,159],"topic":[31],"class_list":["post-5784","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=5784"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5784\/revisions"}],"predecessor-version":[{"id":5785,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5784\/revisions\/5785"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=5784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=5784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=5784"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=5784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}